Jump Financial LLC Has $300,000 Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Jump Financial LLC reduced its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 43.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,868 shares of the biotechnology company’s stock after selling 24,768 shares during the quarter. Jump Financial LLC owned about 0.15% of Enanta Pharmaceuticals worth $300,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nisa Investment Advisors LLC lifted its holdings in Enanta Pharmaceuticals by 417.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,281 shares in the last quarter. Clearstead Advisors LLC acquired a new position in shares of Enanta Pharmaceuticals during the third quarter valued at $57,000. Quantbot Technologies LP boosted its holdings in Enanta Pharmaceuticals by 2,300.0% in the third quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 6,900 shares during the last quarter. Sherbrooke Park Advisers LLC acquired a new stake in Enanta Pharmaceuticals in the third quarter worth about $113,000. Finally, Laurion Capital Management LP acquired a new stake in Enanta Pharmaceuticals in the third quarter worth about $126,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Down 0.4 %

Shares of NASDAQ ENTA opened at $12.03 on Friday. Enanta Pharmaceuticals, Inc. has a twelve month low of $8.08 and a twelve month high of $26.91. The company’s fifty day moving average is $14.34 and its 200-day moving average is $12.40. The stock has a market cap of $254.80 million, a price-to-earnings ratio of -1.93 and a beta of 0.54.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ENTA shares. HC Wainwright reduced their target price on shares of Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday, May 7th. JPMorgan Chase & Co. reduced their price objective on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Thursday, February 8th. JMP Securities dropped their target price on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 7th. Finally, StockNews.com upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $19.00.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.